Theranostics 2022; 12(9):4067-4080. doi:10.7150/thno.72948 This issue

Review

Current update on theranostic roles of cyclophilin A in kidney diseases

Sudarat Hadpech, Visith Thongboonkerd

Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Hadpech S, Thongboonkerd V. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics 2022; 12(9):4067-4080. doi:10.7150/thno.72948. Available from https://www.thno.org/v12p4067.htm

File import instruction

Abstract

Graphic abstract

Cyclophilin A (CyPA) or peptidylprolyl isomerase A (PPIA), an immunophilin with peptidyl-prolyl cis/trans isomerase (PPIase) activity, is an abundant cellular protein widely expressed across various cell types and tissues, including the kidney. Expression of CyPA in the kidney is relatively higher in proximal tubular epithelial cells than others along the nephron. Alterations in expression and secretion of CyPA play important roles in physiological processes and pathophysiology of several diseases affecting the kidney. Herein, we provide a brief overview of CyPA structural biology and present the current update on its theranostic roles in various kidney diseases, including diabetic nephropathy, acute kidney injury, chronic kidney disease, renal fibrosis, and nephrotoxicity associated with organ transplantation. Notably, the diagnostic/prognostic role for urinary CyPA in several of these kidney diseases is promising. Finally, future perspectives on the CyPA research, especially targeting CyPA for therapeutics, are discussed. A comprehensive understanding of the theranostic roles of CyPA in kidney diseases is expected to provide novel insights into the design of new therapeutic interventions and prevention strategies.

Keywords: AKI, Biomarker, CKD, Diabetic nephropathy, Nephrotoxicity, PPIA, Renal fibrosis, Therapeutics